{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:41:58Z","timestamp":1793295718849,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this paper is to critically re-appraise the published trials assessing amitriptyline for migraine prophylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report our methods and results following the Preferred Reporting Items for Systematic Reviews (PRISMA), by searching MEDLINE, EMBASE, Cochrane CENTRAL, and ClinicalTrials.gov for randomized trials of pharmacologic treatments for migraine prophylaxis. We included randomized trials that compared amitriptyline with placebo for migraine prophylaxis in adults. Our outcomes of interest were informed by the Outcome Set for preventive intervention trials in chronic and episodic migraine (COSMIG) and include the proportion of patients who experience a 50% or more reduction in migraine days per month, migraine days per month, and adverse events leading to discontinuation.<\/jats:p>\n                    <jats:p>We assessed risk of bias by using a modified Cochrane RoB 2.0 tool and the certainty of evidence by using the GRADE approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our search yielded 10.826 unique records, of which three trials (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009622) were eligible for data synthesis and analysis. We found moderate certainty evidence that amitriptyline increases the proportion of patients who experience a 50% or more reduction in monthly migraine days, compared to placebo (relative risk: 1.60 (95% CI 1.17 to 2.19); absolute risk difference: 165 more per 1,000 (95% CI 47 more to 327 more). We found moderate certainty evidence that amitriptyline increases the proportion of patients who discontinue due to adverse events compared to placebo (risk difference: 0.05 (95% CI 0.01 to 0.10); absolute risk difference: 50 more per 1,000 (95% CI 10 more to 100 more).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our meta-analysis showed that amitriptyline may have a prophylactic role in migraine patients, however these results are far from robust. This warrants further large-scale research to evaluate the role of amitriptyline in migraine prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-023-01573-6","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T19:02:22Z","timestamp":1681153342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["European Headache Federation (EHF) critical re-appraisal and meta-analysis of oral drugs in migraine prevention\u2014part 1: amitriptyline"],"prefix":"10.1186","volume":"24","author":[{"given":"Christian","family":"Lampl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Versijpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina I.","family":"Deligianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvir","family":"Jassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenVanDenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ornello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Paungarttner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Sanchez-del-Rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Uluduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Zeraatkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"1573_CR1","first-page":"45","volume":"44","author":"AP Friedman","year":"1968","unstructured":"Friedman AP (1968) The migraine syndrome. Bull NY Acad Med 44:45\u201362","journal-title":"Bull NY Acad Med"},{"key":"1573_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1136\/bmj.1.5637.182-d","volume":"1","author":"M Mahloudji","year":"1969","unstructured":"Mahloudji M (1969) Prevention of migraine. BMJ 1:182\u2013183","journal-title":"BMJ"},{"key":"1573_CR3","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.clinthera.2008.12.010","volume":"30","author":"AZ Yaldo","year":"2008","unstructured":"Yaldo AZ, Wertz DA, Rupnow MFT, Quimbo RM (2008) Persistence with migraine prophylactic treatment and acute migraine medication utilization in the managed care setting. Clin Ther 30:2452\u20132460","journal-title":"Clin Ther"},{"issue":"6","key":"1573_CR4","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","volume":"52","author":"E Loder","year":"2012","unstructured":"Loder E, Burch R, Rizzoli P (2012) The 2012 AHS\/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache 52(6):930\u2013945","journal-title":"Headache"},{"issue":"9","key":"1573_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/j.1468-1331.2009.02748.x","volume":"16","author":"S Evers","year":"2009","unstructured":"Evers S, Afra J, Frse A, Goadsby PJ, Linde M, May A, S\u00e1ndor PS (2009) EFNS guideline on the drug treatment of migraine\u2013revised report of an EFNS task force. Eur J Neurol 16(9):968\u2013981","journal-title":"Eur J Neurol"},{"key":"1573_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1468-2982.1993.1303151.x","volume":"13","author":"MD Ferrari","year":"1993","unstructured":"Ferrari MD, Saxena PR (1993) On serotonin and migraine: a clinical and pharmacological review. Cephalalgia 13:151\u2013165","journal-title":"Cephalalgia"},{"issue":"3","key":"1573_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/0333102416640501","volume":"37","author":"M Deen","year":"2017","unstructured":"Deen M, Christensen CE, Hougaard A, Hansen HD, Knudsen GM, Ashina M (2017) Serotonergic mechanisms in the migraine brain - a systematic review. Cephalalgia 37(3):251\u2013264","journal-title":"Cephalalgia"},{"issue":"2","key":"1573_CR8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0014-2999(99)00464-1","volume":"378","author":"AM Gray","year":"1999","unstructured":"Gray AM, Pache DM, Sewell RD (1999) Do alpha2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds? Eur J Pharmacol 378(2):161\u2013168","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"1573_CR9","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.3390\/ijms18112483","volume":"18","author":"H Obata","year":"2017","unstructured":"Obata H (2017) Analgesic Mechanisms of Antidepressants for Neuropathic Pain. Int J Mol Sci. 18(11):2483","journal-title":"Int J Mol Sci."},{"issue":"3","key":"1573_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1023\/A:1020937717260","volume":"24","author":"PG Joshi","year":"1999","unstructured":"Joshi PG, Singh A, Ravichandra B (1999) High concentrations of tricyclic antidepressants increase intracellular Ca2+ in cultured neural cells. Neurochem Res 24(3):391\u2013398","journal-title":"Neurochem Res"},{"issue":"1","key":"1573_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0028-3908(00)00097-6","volume":"40","author":"N Galeotti","year":"2001","unstructured":"Galeotti N, Ghelardini C, Bartolini A (2001) Involvement of potassium channels in amitriptyline and clomipramine analgesia. Neuropharmacology 40(1):5\u201384","journal-title":"Neuropharmacology"},{"issue":"1","key":"1573_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0091270010394852","volume":"52","author":"P Dharmshaktu","year":"2012","unstructured":"Dharmshaktu P, Taya V, Kalra BS (2012) Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 52(1):6\u201317","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1573_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ana.20778","volume":"59","author":"C Ayata","year":"2006","unstructured":"Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 59(4):652\u2013661","journal-title":"Ann Neurol"},{"issue":"2","key":"1573_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s12017-013-8282-6","volume":"16","author":"J Liang","year":"2014","unstructured":"Liang J, Liu X, Pan M, Dai W, Dong Z, Wang X, Liu R, Zheng J, Yu S (2014) Blockade of Nav1.8 currents in nociceptive trigeminal neurons contributes to anti-trigeminovascular nociceptive effect of amitriptyline. Neuromol Med 16(2):308\u2013321","journal-title":"Neuromol Med"},{"key":"1573_CR15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"1573_CR16","doi-asserted-by":"publisher","first-page":"c5222","DOI":"10.1136\/bmj.c5222","volume":"341","author":"JL Jackson","year":"2010","unstructured":"Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M et al (2010) Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 341:c5222","journal-title":"BMJ"},{"key":"1573_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1749-6632.1993.tb26343.x","volume":"703","author":"K Dickersin","year":"1993","unstructured":"Dickersin K, Min YI (1993) Publication bias: the problem that won\u2019t go away. Ann N Y Acad Sci 703:135\u201346. discussion 46-8.","journal-title":"Ann N Y Acad Sci"},{"issue":"11","key":"1573_CR18","doi-asserted-by":"publisher","first-page":"e043242","DOI":"10.1136\/bmjopen-2020-043242","volume":"11","author":"K Haywood","year":"2021","unstructured":"Haywood K, Potter R, Froud R, Pearce G, Box B, Muldoon L et al (2021) Core outcome set for preventive intervention trials in chronic and episodic migraine (COSMIG): an international, consensus-derived and multistakeholder initiative. BMJ Open 11(11):e043242","journal-title":"BMJ Open"},{"issue":"12","key":"1573_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1136\/thoraxjnl-2021-217976","volume":"77","author":"T Pitre","year":"2022","unstructured":"Pitre T, Mah J, Helmeczi W, Khalid MF, Cui S, Zhang M et al (2022) Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Thorax 77(12):1243\u20131250","journal-title":"Thorax"},{"key":"1573_CR20","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","volume":"370","author":"RA Siemieniuk","year":"2020","unstructured":"Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E et al (2020) Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ 370:m2980","journal-title":"BMJ"},{"issue":"1","key":"1573_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, Kuss O, Higgins JP, Langan D, Salanti G (2016) Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 7(1):55\u201379. https:\/\/doi.org\/10.1002\/jrsm.1164. Epub 2015 Sep 2. PMID: 26332144; PMCID: PMC4950030.","journal-title":"Res Synth Methods."},{"key":"1573_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JPTJ Higgins","year":"2019","unstructured":"Higgins JPTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (2019) Cochrane Handbook for Systematic Reviews of Interventions, 2nd edn. Wiley, Chichester","edition":"2"},{"issue":"32","key":"1573_CR23","doi-asserted-by":"publisher","first-page":"E901","DOI":"10.1503\/cmaj.200077","volume":"192","author":"S Schandelmaier","year":"2020","unstructured":"Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA et al (2020) Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. Can Med Assoc J 192(32):E901","journal-title":"Can Med Assoc J"},{"issue":"7109","key":"1573_CR24","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634","journal-title":"BMJ"},{"key":"1573_CR25","doi-asserted-by":"crossref","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial.\u00a0Evid Based Ment Health 22(4):153\u2013160","DOI":"10.1136\/ebmental-2019-300117"},{"issue":"3","key":"1573_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw. 36(3):1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03","journal-title":"J Stat Softw."},{"issue":"7650","key":"1573_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"key":"1573_CR28","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2021.03.026","volume":"137","author":"L Zeng","year":"2021","unstructured":"Zeng L, Brignardello-Petersen R, Hultcrantz M, Siemieniuk RAC, Santesso N, Traversy G et al (2021) GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings. J Clin Epidemiol 137:163\u2013175","journal-title":"J Clin Epidemiol"},{"key":"1573_CR29","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","volume":"119","author":"N Santesso","year":"2020","unstructured":"Santesso N, Glenton C, Dahm P, Garner P, Akl EA, Alper B et al (2020) GRADE guidelines informative statements to communicate the findings of systematic reviews of interventions. J Clin Epidemiol 119:126\u2013135","journal-title":"J Clin Epidemiol"},{"key":"1573_CR30","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/jnnp.36.4.684","volume":"36","author":"JD Gomersall","year":"1973","unstructured":"Gomersall JD, Stuart A (1973) Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psych 36:684\u2013690","journal-title":"J Neurol Neurosurg Psych"},{"key":"1573_CR31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/archneur.1979.00500470065013","volume":"36","author":"JR Couch","year":"1979","unstructured":"Couch JR, Hassanein RS (1979) Amitriptyline in migraine prophylaxis. Arch Neurol 36:695\u2013699","journal-title":"Arch Neurol"},{"key":"1573_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3923\/ijp.2005.366.368","volume":"1","author":"M Rafieian-Kopaei","year":"2005","unstructured":"Rafieian-Kopaei M, Mehvari J, Shirzadeh H (2005) Different profile of propranolol and amitriptyline effects on migraine prophylaxis. Int J Pharmacol 1:366\u2013368","journal-title":"Int J Pharmacol"},{"issue":"1","key":"1573_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1526-4610.2010.01800.x","volume":"51","author":"JR Couch","year":"2011","unstructured":"Couch JR (2011) Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 51(1):33\u201351","journal-title":"Headache"},{"issue":"10","key":"1573_CR34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1136\/jnnp-2016-313458","volume":"87","author":"AL Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves AL, Martini Ferreira A, Ribeiro RT, Zukerman E, Cipolla-Neto J, Peres MF (2016) Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention. J Neurol Neurosurg Psychiatry 87(10):1127\u20131132","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"1573_CR35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/j.1468-2982.2005.00956.x","volume":"25","author":"MS Berilgen","year":"2005","unstructured":"Berilgen MS, Bulut S, Gonen M, Tekatas A, Dag E, Mungen B (2005) Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 25(11):1048\u20131053","journal-title":"Cephalalgia"},{"issue":"2","key":"1573_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2217\/pme-2021-0022","volume":"19","author":"L MifsudBuhagiar","year":"2022","unstructured":"MifsudBuhagiar L, Casha M, Grech A, SerracinoInglott A, LaFerla G (2022) The interplay between pharmacogenetics, concomitant drugs and blood levels of amitriptyline and its main metabolites. Per Med 19(2):113\u2013123","journal-title":"Per Med"},{"issue":"9","key":"1573_CR37","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/archneur.1992.00530330036012","volume":"49","author":"BK Rasmussen","year":"1992","unstructured":"Rasmussen BK, Jensen R, Schroll M, Olesen J (1992) Interrelations between migraine and tension-type headache in the general population. Arch Neurol 49(9):914\u2013918","journal-title":"Arch Neurol"},{"key":"1573_CR38","doi-asserted-by":"publisher","first-page":"840","DOI":"10.7326\/0003-4819-137-10-200211190-00014","volume":"137","author":"V Snow","year":"2002","unstructured":"Snow V, Weiss K, Wall EM, Mottur-Pilson C (2002) Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Int Med 137:840\u2013849","journal-title":"Ann Int Med"},{"issue":"17","key":"1573_CR39","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"SD Silberstein","year":"2012","unstructured":"Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E (2012) Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence based guideline update: pharmacological treatment for episodci migrainbe prevention in adults. Neurology 78(17):1337\u2013134","journal-title":"Neurology"},{"key":"1573_CR40","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/jnnp-2015-312233","volume":"87","author":"MT Minen","year":"2016","unstructured":"Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, Silbersweig D (2016) Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry 87:741\u2013749","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1573_CR41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1468-1331.2009.02631.x","volume":"16","author":"C Lampl","year":"2009","unstructured":"Lampl C, Huber G, Adl J, Lutrhingshausen G, Franz G, Marecek S, Weber J, Baumhackl U, Mueller T (2009) Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors. Eur J Neurol 16:943\u2013948","journal-title":"Eur J Neurol"},{"key":"1573_CR42","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0022-3956(93)90006-N","volume":"27","author":"JA Haythornthwaite","year":"1993","unstructured":"Haythornthwaite JA (1993) Migraine headaches and psychopathology: future directions. J Psychiatr Res 27:183\u2013186","journal-title":"J Psychiatr Res"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01573-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-023-01573-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-023-01573-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T19:02:25Z","timestamp":1681153345000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-023-01573-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1573"],"URL":"https:\/\/doi.org\/10.1186\/s10194-023-01573-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2673135\/v1","asserted-by":"object"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jakob Paungarttner, Tessa de Vries and Dena Zeraatkar report no conflict of interest.Christian Lampl has received consulting fees and honoraria for lectures\/presentations from AbbVie\/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva. CL participated in clinical trials as the principal investigator for Eli Lilly. Intellectual Christian Lampl is president of the European Headache Federation and associate editor for The Journal of Headache and Pain.Jan Versijpt received personal fees and nonfinancial support from Teva, personal fees from Novartis and Lundbeck, and grants and nonfinancial support from Allergan\/Abbvie. Jan Versijpt serves as a member of the Board of Directors in the European Headache Federation.Faisal Mohammad Amin has received honoraria for delivering lectures and\/or participation in advisory boards for Pfizer, Teva, Lundbeck, Novartis and Eli Lilly. Faisal Mohammad Amin serves as associate editor for the journals Headache Medicine, Acta Neurologica Scandinavica, Frontiers in Neurology and Frontiers In Pain Research. Faisal Mohammad Amin serves as president of the Danish Headache Society and a member of the Board of Directors in European Headache Federation.Christina I Deligianni has received HIS research fellowship grant, scholarship from Hellenic society of Neurology. Christina I Deligianni serves as a member of the Board of Directors in the European Headache Federation.Raquel Gil-Gouveia reports honoraria for lectures\/presentations from AbbVie\/Allergan, Eli Lily, Lundbeck, Novartis, Teva, Organon, Pfizer; participated in clinical trials as the principal investigator for AMGEN, Novartis, Lundbeck. research grants from Novartis. Raquel Gil-Gouveia serves as a member of the Board of Directors in European Headache Federation.Antoinette MaassenVanDenBrink received honoraria, research and\/or travel grants from Allergan\/Abbvie, Amgen\/Novartis, Eli Lilly, Satsuma and Teva as principal investigator. Intellectual Antoinette MaassenVanDenBrink is vice-president of the European Headache Federation and associate editor for The Journal of Headache and Pain.Raffaele Ornello reports personal fees from Eli Lilly, Novartis, and Teva, and non-financial support from Allergan\/AbbVie, Novartis, and Teva; he is member of the Junior Editorial Board of \u201cThe Journal of Headache and Pain\u201d and is Associate Editor in Headache and Neurogenic Pain for \u201cFrontiers in Neurology\u201d.Margarita Sanchez-del-Rio has received consulting fees and honoraria for lectures\/presentations from Eli Lily, Lundbeck, Novartis, Teva and Pfizer. Intellectual as Secretary of the European Headache Federation, Review Editor on the Editorial Board of Headache and Neurogenic Pain (specialty section of Frontiers in Neurology). Margarita Sanchez-del-Rio serves as a member of the Board of Directors in the European Headache Federation.Uwe Reuter has received consulting fees, research grants or fees for presentations from Abbie, Allegan, Amgen, Lilly, Lundbeck, Medscape, Novartis, Pfizer, StreaMedup, Teva and the German Government (BMBF). Uwe Reuter is treasurer of the European Headache Federation.Derya Uluduz receives honoraria from Allergan-Abbvie, TEVA; consulting fees and honoraria for lectures\/presentations from Eli Lily, Novartis, Allergan\/Abbvie and Neutec participated in clinical trials as the sub-investigator for AMGEN, Novartis. Derya Uluduz serves as a member of the Board of Directors in the European Headache Federation.Simona Sacco reports personal fees as speaker or advisor for Abbott, Allergan-Abbvie, AstraZeneca, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Pfizer, Teva; research grants from Novartis and Uriach; fees for CME\/education from Medscape and Neurodiem Ology Medical Education; Intellectual as president elect European Stroke Organisation, second vice president of the European Headache Federation, specialty chief editor in Headache and Neurogenic Pain for Frontiers in Neurology, associate editor for The Journal of Headache and Pain, assistant editor for Stroke.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}